Pipeline Report: October 2020 | Articles

Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC

October 26th 2020

The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.

MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases

October 23rd 2020

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential therapies to treat brain metastases and those with cancers refractory to available therapies.

DisTinGuish Trial Doses First Patient With Investigational Dickkopf-1 Antibody DKN-01 Plus Tislelizumab in Gastric/GEJ Cancer

October 19th 2020

The first patient has officially been dosed with investigational anti-Dickkopf-1 antibody plus tislelizumab with or without chemotherapy as part of the ongoing phase 2a DisTinGuish study (NCT04363801) in patients with gastric or gastroesophageal junction cancer.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Clinical Collaboration Underway for Nirogacestat/Teclistamab Combo in Myeloma

October 12th 2020

SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat is slated to be evaluated in combination with Janssen Biotech, Inc.’s BCMA- and CD3-targeted bispecific antibody, teclistamab in a phase 1 study in patients with relapsed/refractory multiple myeloma.

Immunomedics Acquisition Transfers Development of Sacituzumab Govitecan to Gilead Sciences

October 8th 2020

Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.